Granulomatosis With Polyangiitis Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies-InflaRx GmbH, Bristol-Myers Squib, Hoffmann-La Roche, Iqvia Pty Ltd

Granulomatosis With Polyangiitis Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies-InflaRx GmbH, Bristol-Myers Squib, Hoffmann-La Roche, Iqvia Pty Ltd

June 09
14:15 2023
Granulomatosis With Polyangiitis Clinical Trials | A Drug Pipeline Analysis Report 2023 | Companies-InflaRx GmbH, Bristol-Myers Squib, Hoffmann-La Roche, Iqvia Pty Ltd
DelveInsight Business Research LLP
DelveInsight’s “Granulomatosis with Polyangiitis – Pipeline Insight, 2023” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Granulomatosis with Polyangiitis pipeline landscape.

DelveInsight’s “Granulomatosis with Polyangiitis – Pipeline Insight, 2023” report provides comprehensive insights about 2+ companies and 2+ pipeline drugs in Granulomatosis with Polyangiitis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Key Takeaways from the Granulomatosis With Polyangiitis Pipeline Report

  • Over 2+ companies and 2+ pipeline drugs Granulomatosis With Polyangiitis, pipeline therapies are in various stages of development, and their anticipated acceptance in the Granulomatosis With Polyangiitis market would significantly increase market revenue. 

  • Leading Granulomatosis With Polyangiitis companies developing novel drug candidates are InflaRx GmbH, Bristol-Myers Squibb, Hoffmann-La Roche, Iqvia Pty Ltd, and many others

  • Promising Granulomatosis With Polyangiitis pipeline therapies in various stages of development include Abatacept, IFX-1, and others.

Granulomatosis With Polyangiitis Overview

Granulomatosis with Polyangiitis formerly known as Wegener’s granulomatosis is an uncommon disorder that causes inflammation of the blood vessels in your nose, sinuses, throat, lungs, and kidneys. It is classified as an autoimmune disorder. It is the result of inflammation within the tissues called granulomatous inflammation and blood vessel inflammation (“vasculitis”), which can damage organ systems. The areas most commonly affected by GPA include the sinuses, lungs, and kidneys, but any site can be affected. Granulomatosis with Polyangiitis is nearly equally distributed between the gender, with a slight male predominance. Granulomatosis with Polyangiitis typically occurs in middle age but is found in people of all ages.

Discover more about the emerging Granulomatosis With Polyangiitis drugs @ Granulomatosis With Polyangiitis Treatment Drugs

Granulomatosis With Polyangiitis Pipeline Therapies and Key Companies

  • IFX-1 (Vilobilemab):InflaRx GmbH

And  many others 

Granulomatosis With Polyangiitis Pipeline Therapeutics Assessment

DelveInsight’s Report covers around 20+ products under different phases of clinical development like

  • Mid-stage products (Phase II and Phase I/II)

  • Early-stage products (Phase I/II and Phase I) along with the details of

  • Pre-clinical and Discovery stage candidates

  • Discontinued & Inactive candidates

  • Route of Administration

Granulomatosis With Polyangiitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Subcutaneous

  • Intravenous

  • Intramuscular

  • Molecule Type

 Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins

  • Small molecule

  • Monoclonal antibody

  • Peptide

  • Polymer

  • Gene therapy

Drugs have been categorized under various product types like Mono, Combination, and Mono/Combination.

Scope of the Granulomatosis With Polyangiitis Pipeline Report 

  • Coverage: Global 

  • Key Granulomatosis With Polyangiitis  Companies: InflaRx GmbH, Bristol-Myers Squib, Hoffmann-La Roche, Iqvia Pty Ltd, and many others.

  • Key Granulomatosis With Polyangiitis  Pipeline Therapies: Abatacept, IFX-1, and many others.

Find out more about the Granulomatosis With Polyangiitis treatment options in development @ Granulomatosis With Polyangiitis Clinical Trials

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Pipeline Therapeutics

5. Late-Stage Products (Phase III)

6. Mid-Stage Products (Phase  II)

7. Early Stage Products (Phase  I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Therapeutic Assessment

11. Inactive Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Unmet Needs

14. Market Drivers and Barriers

15. Appendix

16. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Categories